

Additional file 2: Table of contents

Figure S1: VAP-incidence proportion: observational studies (Benchmark groups)	2
Figure S2: VAP-incidence proportion: studies of VAP prevention using non-antibiotic methods	3
Figure S3: VAP-incidence proportion: control groups of studies of VAP prevention using SDD	4
Figure S4: VAP-incidence proportion: intervention groups of studies of VAP prevention using SDD	5

VAP incidence - Benchmark groups




Figure S1. Caterpillar plots of the group specific (small diamonds) and summary (large open diamond, broken vertical line) VAP-incidence proportion and 95 % CI of observational studies (Benchmark groups). Studies are listed in Table S1. Note that the x axis is a logit scale.

VAP incidence Non-antibiotic methods




Figure S2. Caterpillar plots of the group specific (small diamonds) and summary (large open diamond, broken vertical line) VAP-incidence proportion and 95 % CI of control and intervention groups of studies of VAP prevention using non-antibiotic methods. For comparison, the summary VAP -IP (vertical line) derived from the benchmark groups from figure S1 is shown. Studies are listed in Table S2. Note that the x axis is a logit scale.

VAP incidence Antibiotic methods - control groups




Figure S3. Caterpillar plots of the group specific (small diamonds) and summary (large open diamond) VAP-incidence proportion and 95 % CI of control groups of studies of VAP prevention using SDD for which the control groups did not or did receive topical placebo. For comparison, the summary VAP- IP (vertical line) derived from the benchmark groups from figure S1 are shown. Studies are listed in Tables S3, S4 & S5. Note that the x axis is a logit scale.

VAP incidence

Antibiotic methods - intervention groups




Figure S4. Caterpillar plots of the group specific (small diamonds) and summary (large open diamond) VAP-incidence proportion and 95 % CI of intervention groups of studies of VAP prevention using SDD for which the control groups did not or did receive topical placebo. For comparison, the summary VAP-IP (vertical line) derived from the benchmark groups from figure S1 are shown. Studies are listed in Tables S3, S4 and S5. Note that the x axis is a logit scale.